Stonegate Investment Group, LLC Biocryst Pharmaceuticals Inc Transaction History
Stonegate Investment Group, LLC
- $3.35 Billion
- Q2 2024
A detailed history of Stonegate Investment Group, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Stonegate Investment Group, LLC holds 49,588 shares of BCRX stock, worth $365,959. This represents 0.01% of its overall portfolio holdings.
Number of Shares
49,588
Previous 49,588
-0.0%
Holding current value
$365,959
Previous $251,000
21.91%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
257Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$147 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$139 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$92.8 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$69 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$65.1 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.37B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...